Abstract 19P
Background
SCLC is highly heterogeneous and can be divided into NE (Neuroendocrine)-high and NE-low groups according to 50 genes on transcriptomic level, harboring different immune microenvironments and potential immunotherapy reactivity. However, this is still far from clinical application since the current three classic NE markers (ChrA, Syn,and CD56) are not very satisfactory either for specificity or sensitivity. It is necessary to explore novel NE markers, that are both close to NE gene subtyping and feasible for clinicopathological use.
Methods
Quantitative detection of NE mRNA genes by Nanostring nCounter as well as INSM1 protein by immunohistochemistry was performed simultaneously on 48 whole slides as testing group. Spearman correlation was applied for consistency analysis of 50 genes and INSM1 protein expression, and the best cut-off for INSM1 expression was validated on 247 tissue microarrays for comparison of the 3 traditional NE protein markers for specificity and sensibility as well as prognostic significance.
Results
In 48 cases, quantitative detection revealed 83.3% for NE-high and 16.7% for NE-low, while for INSM1 protein grouping, it was 79.2% (H-score>100) for NE(INSM1)-high and 20.8% (H-score<=100) for NE(INSM1)-low. NE subtypes defined by INSM1 protein and NE genes had significant consistency in terms of proportion (p=0.026). In addition, NE groups also had consistent clinical characteristics and prognostic trend in the two levels. Patients with NE-high and NE(INSM1)-high tended to be in the advanced stage. Patients with NE-high and NE(INSM1)-high subtypes have a tendency to poor prognosis. In 247 cases of validation exploration, INSM1 expression was positively correlated with 3 classical markers, moreover, in triple-negative cases, INSM1 showed a favorable positive rate (1.5%, 3/198). In addition, NE(INSM1)-high patients showed more bronchial invasion and tumor thrombosis than that of NE(INSM1)-low ones (p<0.05), and the OS rates in the NE(INSM1)-high group were slightly lower than those in the NE(INSM1)-low group.
Conclusions
INSM1 has great potential as a marker of NE differentiation and subgrouping, and also shows a certain correlation with prognosis and some clinicopathological factors.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract